1379 related articles for article (PubMed ID: 23041453)
21. Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study.
Bergmann L; Goebell PJ; Kube U; Kindler M; Herrmann E; Janssen J; Schmitz J; Weikert S; Steiner G; Jakob A; Staehler MD; Steiner T; Overkamp F; Albrecht M; Guderian G; Doehn C
Onkologie; 2013; 36(3):95-100. PubMed ID: 23485996
[TBL] [Abstract][Full Text] [Related]
22. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.
Garcia JA; Hudes GR; Choueiri TK; Stadler WM; Wood LS; Gurtler J; Bhatia S; Joshi A; Hozak RR; Xu Y; Schwartz JD; Thompson JA
Cancer; 2014 Jun; 120(11):1647-55. PubMed ID: 24577874
[TBL] [Abstract][Full Text] [Related]
23. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
[TBL] [Abstract][Full Text] [Related]
25. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
26. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
27. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.
Guillot A; Levy A; Pacaut C; Collard O; Massard C; Merrouche Y; Magné N
Clin Genitourin Cancer; 2012 Sep; 10(3):147-52. PubMed ID: 22796529
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.
Ishihara H; Takagi T; Kondo T; Tachibana H; Yoshida K; Omae K; Iizuka J; Kobayashi H; Tanabe K
Int J Clin Oncol; 2018 Jun; 23(3):559-567. PubMed ID: 29327159
[TBL] [Abstract][Full Text] [Related]
29. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
[TBL] [Abstract][Full Text] [Related]
30. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
31. [Metastatic renal cell carcinoma treated with everolimus--data from the RENIS Clinical Registry].
Büchler T; Dusek L; Fínek J; Poprach A; Budnáková D; Kandrnal V; Jarkovský J; Bortlícek Z; Klimes D; Abrahámová J; Vyzula R
Klin Onkol; 2011; 24(5):389-92. PubMed ID: 22070021
[TBL] [Abstract][Full Text] [Related]
32. No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.
Miyazaki A; Miyake H; Harada K; Fujisawa M
Anticancer Res; 2015 May; 35(5):3067-73. PubMed ID: 25964597
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy in metastatic renal cell cancer.
Ravaud A; Gross-Goupil M; Bellmunt J
Semin Oncol; 2013 Aug; 40(4):472-81. PubMed ID: 23972711
[TBL] [Abstract][Full Text] [Related]
34. Second-line therapy for refractory renal-cell carcinoma.
Zustovich F; Lombardi G; Nicoletto O; Pastorelli D
Crit Rev Oncol Hematol; 2012 Jul; 83(1):112-22. PubMed ID: 21944739
[TBL] [Abstract][Full Text] [Related]
35. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
Park JY; Lee JL; Baek S; Eo SH; Go H; Ro JY; Cho YM
Hum Pathol; 2014 Jul; 45(7):1437-44. PubMed ID: 24784922
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
[TBL] [Abstract][Full Text] [Related]
37. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
Alimohamed N; Lee JL; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Tantravahi S; Kollmannsberger C; North S; Rini BI; Choueiri TK; Heng DY
Clin Genitourin Cancer; 2014 Aug; 12(4):e127-31. PubMed ID: 24485801
[TBL] [Abstract][Full Text] [Related]
38. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
[TBL] [Abstract][Full Text] [Related]
39. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Bailey EB; Tantravahi SK; Poole A; Agarwal AM; Straubhar AM; Batten JA; Patel SB; Wells CE; Stenehjem DD; Agarwal N
Clin Genitourin Cancer; 2015 Jun; 13(3):e131-7. PubMed ID: 25497584
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]